CPS1-IT1: A Potential Drug Target and Biomarker (G29034)

Target Name: CPS1-IT1

NCBI ID: G29034

CPS1-IT1

Other Name(s): CPS1IT | CPS1 intronic transcript 1 | CPS1IT1 | CPS1-IT | PRO0132

CPS1-IT1: A Potential Drug Target and Biomarker

CPS1-IT1 is a protein that is expressed in various tissues of the body, including the brain, spleen, and lymphoid organs. It is a key regulator of the immune response and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Recent studies have identified CPS1-IT1 as a potential drug target and biomarker for a variety of diseases. In this article, we will explore the biology and potential therapeutic applications of CPS1-IT1.

The biology of CPS1-IT1

CPS1-IT1 is a 21-kDa protein that is expressed in the cytoplasm of various cell types. It is composed of a N-terminal transmembrane domain, a catalytic domain, and a C-terminal cytoplasmic domain. The transmembrane domain is responsible for the protein's ability to interact with various cell signaling pathways, while the catalytic domain is responsible for its catalytic activity. The C-terminal domain is involved in the regulation of cellular processes such as cell adhesion and migration.

CPS1-IT1 has been shown to play a role in the regulation of cellular immune responses, including the regulation of T cell development and function. It has been shown to promote the activation and proliferation of T cells, as well as the production of antibodies by B cells.

In addition to its role in immune regulation, CPS1-IT1 has also been shown to play a role in the regulation of cellular processes such as cell adhesion, migration, and the regulation of the cytoskeleton.

Potential therapeutic applications of CPS1-IT1

The potential therapeutic applications of CPS1-IT1 are vast, and there is significant interest in its use as a drug target.

One of the main potential therapeutic applications of CPS1-IT1 is its potential as a cancer therapeutic. CPS1-IT1 has been shown to promote the growth and survival of various cancer cell types, including breast, lung, and ovarian cancer. Therefore, CPS1-IT1 may be a useful target for cancer therapies that target immune cells, such as cancer vaccines or adoptive T cell therapy.

Another potential therapeutic application of CPS1-IT1 is its role in the treatment of neurodegenerative diseases. CPS1-IT1 has been shown to contribute to the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Therefore, CPS1-IT1 may be a useful target for therapies that aim to slow the progression of these diseases.

In addition to its potential therapeutic applications, CPS1-IT1 is also a potential biomarker for a variety of diseases. Its expression has been shown to be elevated in a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Therefore, CPS1-IT1 may be a useful biomarker for the diagnosis and monitoring of these diseases.

Conclusion

In conclusion, CPS1-IT1 is a protein that has significant potential as a drug target and biomarker for a variety of diseases. Its role in the regulation of cellular immune responses and its expression in various tissues make it an attractive target for therapies that aim to improve immune function or treat diseases that are characterized by inflammation or cellular dysfunction. Further research is needed to fully understand the biology of CPS1-IT1 and its potential therapeutic applications.

Protein Name: CPS1 Intronic Transcript 1

The "CPS1-IT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CPS1-IT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets